Clinical and biologic disease characteristics of patients with multiple myeloma, according to type of treatment
| Characteristic . | Treatment group . | P . | |
|---|---|---|---|
| ASCT (n = 47) . | Chemotherapy (n = 40) . | ||
| Mean age, y (range) | 55 (31-70) | 56 (32-70) | .3 |
| Sex: M/F (%) | 43/57 | 42/58 | .9 |
| Immunoglobulin isotype (%) | |||
| IgG | 60 | 58 | .6 |
| IgA | 28 | 22 | |
| BJ | 8 | 20 | |
| Other | 4 | 0 | |
| Clinical disease stage II/III (%) | 61/39 | 58/42 | .9 |
| Serum creatinine at least 178 μmol/L (%) | 9 | 13 | .7 |
| Hemoglobin less than 100 g/L (%) | 38 | 32 | .8 |
| Calcium greater than 2.9 mmol/L (%) | 13 | 14 | .8 |
| Albumin less than 30 g/L (%) | 27 | 19 | .4 |
| LDH greater than 460 U (%) | 7 | 6 | .9 |
| β2-microglobulin at least 60 mg/L (%) | 28 | 30 | .9 |
| C-reactive protein at least 60 g/L (%) | 21 | 11 | .5 |
| ECOG grade at least 2 (%) | 34 | 53 | .3 |
| Diploid DNA content (%) | 43 | 49 | .5 |
| S-phase plasma cells at least 3% (%) | 16 | 26 | .4 |
| BMPCs, % (range) | 35 (4-92) | 45 (8-99) | .3 |
| Median follow-up (mo) | 62 | 60 | .6 |
| Characteristic . | Treatment group . | P . | |
|---|---|---|---|
| ASCT (n = 47) . | Chemotherapy (n = 40) . | ||
| Mean age, y (range) | 55 (31-70) | 56 (32-70) | .3 |
| Sex: M/F (%) | 43/57 | 42/58 | .9 |
| Immunoglobulin isotype (%) | |||
| IgG | 60 | 58 | .6 |
| IgA | 28 | 22 | |
| BJ | 8 | 20 | |
| Other | 4 | 0 | |
| Clinical disease stage II/III (%) | 61/39 | 58/42 | .9 |
| Serum creatinine at least 178 μmol/L (%) | 9 | 13 | .7 |
| Hemoglobin less than 100 g/L (%) | 38 | 32 | .8 |
| Calcium greater than 2.9 mmol/L (%) | 13 | 14 | .8 |
| Albumin less than 30 g/L (%) | 27 | 19 | .4 |
| LDH greater than 460 U (%) | 7 | 6 | .9 |
| β2-microglobulin at least 60 mg/L (%) | 28 | 30 | .9 |
| C-reactive protein at least 60 g/L (%) | 21 | 11 | .5 |
| ECOG grade at least 2 (%) | 34 | 53 | .3 |
| Diploid DNA content (%) | 43 | 49 | .5 |
| S-phase plasma cells at least 3% (%) | 16 | 26 | .4 |
| BMPCs, % (range) | 35 (4-92) | 45 (8-99) | .3 |
| Median follow-up (mo) | 62 | 60 | .6 |
ASCT indicates autologous stem cell transplantation; LDH, lactic dehydrogenase; ECOG, Eastern Cooperative Oncology Group; and BMPCs, bone marrow plasma cells.